最新临床试验：帕博西林联合来曲唑或氟维司坦治疗老年人雌激素受体阳性、HER2阴性转移性乳腺癌

这项一项II期的临床试验，目的是研究帕博西林、来曲唑或氟维司特治疗老年人雌激素受体阳性、Her2阴性乳腺癌（已扩散到身体其他部位）的副作用和效果。帕博西林可能通过阻断细胞生长所需的某些酶来阻止肿瘤细胞的生长。用于化疗的药物，如来曲唑或氟维司坦，以不同的方式阻止肿瘤细胞的生长，要么杀死细胞，要么阻止它们分裂，要么阻止它们扩散。给予帕博西林和来曲唑或氟维司特来治疗乳腺癌可能效果更好。

This phase II trial studies the side effects and how well palbociclib and letrozole or fulvestrant works in treating patients with estrogen receptor positive, HER2 negative breast cancer that has spread to other places in the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as letrozole or fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib and letrozole or fulvestrant may work better in treating patients with breast cancer.

Primary ID A171601
Secondary IDs NCI-2017-01596
Clinicaltrials.gov ID NCT03633331

Status: Active
Age: 70 years and over
Gender: Male or Female
Location: 203 locations